Maturitas
Volume 56, Issue 3 , Pages 257-262, 20 March 2007

Dry eye in post-menopausal women using hormone replacement therapy

  • Uzeyir Erdem

      Affiliations

    • Department of Ophthalmology, Gulhane Military Medical Faculty, 06018 Etlik, Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 312 3237835; fax: +90 312 3045850.
  • ,
  • Ozlem Ozdegirmenci

      Affiliations

    • T.C.S.B Etlik Women Hospital, Ankara, Turkey
  • ,
  • Emine Sobaci

      Affiliations

    • T.C.S.B Etlik Women Hospital, Ankara, Turkey
  • ,
  • Güngör Sobaci

      Affiliations

    • Department of Ophthalmology, Gulhane Military Medical Faculty, 06018 Etlik, Ankara, Turkey
  • ,
  • Umit Göktolga

      Affiliations

    • Department of Obstetrics & Gynecology, Gulhane Military Medical Faculty, Ankara, Turkey
  • ,
  • Selim Dagli

      Affiliations

    • Department of Ophthalmology, Gulhane Military Medical Faculty, 06018 Etlik, Ankara, Turkey

Received 12 February 2006; received in revised form 22 August 2006; accepted 25 August 2006. published online 18 September 2006.

Abstract 

Purpose

To evaluate the effect of hormone replacement therapy (HRT) on dry eye in post-menopausal women.

Methods

Forty post-menopausal women with dry eye (20 patients, group 1) and without dry eye (20 patients, group 2), and planning to receive HRT (estrogen plus progesterone), were recruited as the study groups. Forty age-matched untreated women were enrolled as controls (group 3 with dry eye, 5 patients; group 4 without dry eye, 35 patients). Patients having at least one of the symptoms (dryness, itching, photophobia, foreign body sensation, and tearing) together with two of the tests with positive results for dry eye (tear film break-up time (BUT), fluorescein staining of the cornea, analysis of the meibomian gland, and Schirmer I test) in both eyes were considered dry eye positive. Hormonal assay for follicle stimulating hormone, luteinizing hormone, estradiol, and free testosterone was performed. Dry eye statuses in the groups were evaluated statistically.

Results

Four patients with incomplete follow-up data were excluded. HRT use increased estrodiol levels in the groups. Mean ages of patients (50.2±4.8 and 50.7±3.9 years, and 50.0±4.6 and 53.0±3.9 years) were similar (p=0.67). Duration of menopause in groups 1 and 2 (3.2±2.2 and 1.4±1.2 years; p=0.01), and in groups 3 and 4 (3.0±1.6 and 1.7±1.3 years; p=0.014) were different. At the third month examinations, all of the patients in group 1, and 11 patients (61.1%) in group 2 had dry eye (p=0.003).

Conclusion

Duration of menopause and use of HRT may increase the incidence of dry eye in post-menopausal woman.

Keywords: Hormone replacement therapy, Dry eye, Menopause

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0378-5122(06)00311-2

doi:10.1016/j.maturitas.2006.08.007

Maturitas
Volume 56, Issue 3 , Pages 257-262, 20 March 2007